In vivo CAR-T engineering: insights from the 2025 ASH annual meeting.

IF 17.5 1区医学 Q1 HEMATOLOGY

Experimental Hematology & Oncology Pub Date : 2026-02-26 DOI:10.1186/s40164-026-00762-8

Gelayol Asadi, Misagh Rajabinejad

引用次数: 0

Abstract

In vivo chimeric antigen receptor (CAR)-T engineering is a prominent field of research in cancer immunology, in which vectors are used to reprogram endogenous T-cells into CAR-T cells. Viral and nonviral platforms presented at the 67th Annual Meeting of the American Society of Hematology (ASH) offer precise T-cell targeting and efficient CAR expression. Preclinical models demonstrated robust generation of CAR-T cells, potent tumor clearance, and strong clinical translational potential. However, certain limitations remained to be addressed in future studies. This correspondence summarizes the key findings from the meeting, discusses current translational challenges, and highlights future directions.

查看原文本刊更多论文

体内CAR-T工程：来自2025年ASH年会的见解。

体内嵌合抗原受体（CAR -T）工程是癌症免疫学的一个重要研究领域，它利用载体将内源性t细胞重编程为CAR-T细胞。第67届美国血液学学会（ASH）年会上提出的病毒和非病毒平台提供了精确的t细胞靶向和有效的CAR表达。临床前模型显示了强大的CAR-T细胞生成，强大的肿瘤清除能力和强大的临床转化潜力。然而，在未来的研究中仍有一些局限性有待解决。本文总结了会议的主要发现，讨论了当前的翻译挑战，并强调了未来的方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental Hematology & Oncology Medicine-Oncology

CiteScore

12.60

自引率

7.30%

发文量

审稿时长

6 weeks

期刊介绍： Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings. Experimental Hematology & Oncology publishes original work, hypothesis, commentaries and timely reviews. With open access and rapid turnaround time from submission to publication, the journal strives to be a hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the closely related fields of hematology and oncology.